Company Overview
Polyrizon Ltd. is a biotechnology entity focused on the development of medical device hydrogels formulated as nasal sprays within the Israeli market. This company operates within the Healthcare sector, specifically targeting the Biotechnology industry, an environment where innovation in therapeutic delivery systems and allergen management is critical for advancing patient care capabilities. The organization's scale is defined by a market capitalization of $12.50M, while specific figures for annual revenue and employee count are not disclosed in the available data. These valuation metrics indicate that the company holds a position as a small-cap biotechnology firm, suggesting a developmental stage where capital allocation is heavily weighted toward research and product advancement rather than mature commercial scaling.
Financial Health
The company reports a Net Income (TTM) of $-3,335,000 and an EBITDA of $-5,907,000, with Revenue (TTM) figures listed as N/A in the provided data. The absence of reported revenue alongside significant net losses highlights a cost structure typical of early-stage biotechnology firms, where expenses related to proprietary technology development and clinical trials substantially exceed current income generation. Free Cash Flow stands at $-4,659,625, indicating that the company is burning cash to fund operations and R&D activities rather than generating surplus liquidity for immediate distribution to shareholders. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the current inability to realize profit from sales or operations due to the lack of substantial revenue volume relative to high operational costs. On the balance sheet, the company holds $11.49M in cash against N/A debt, resulting in a Debt to Equity ratio that is N/A, which suggests a conservative capital structure free of traditional interest-bearing liabilities at this time. The Current Ratio is an exceptionally high 29.03, indicating robust short-term liquidity and a substantial buffer against immediate obligations despite the negative cash flow situation. Return on Equity is -25.4% and Return on Assets is -28.9%, metrics that reveal management is currently deploying capital to generate losses rather than positive returns, a common characteristic for biotech companies in the pre-revenue or late-stage development phases where reinvestment is prioritized over immediate profitability.
Valuation Assessment
Trailing P/E and Forward P/E ratios are both N/A, as the company has not generated positive earnings to support these standard valuation multiples, implying that earnings-based trajectory analysis is not currently applicable to this asset. The Price to Book ratio is 0.64, indicating that the market values the company at a discount to its book value, which often occurs when investors price in the risk associated with converting intangible assets or R&D investments into tangible equity. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-0.33) provide further context, with the negative EV/EBITDA reflecting the company's negative earnings before interest, taxes, depreciation, and amortization relative to its enterprise value. The stock has experienced significant volatility over the last year, with a 52-Week High of $2235.00 and a 52-Week Low of $2.88, placing the current trading price in a range that reflects extreme price discovery typical of micro-cap biotechnology stocks with limited historical trading data. The Beta is N/A, preventing a direct assessment of price volatility relative to the broader market, though the wide spread between the high and low suggests high sensitivity to market sentiment and sector-specific news.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both N/A, meaning there is no historical data available to determine if earnings are growing faster or slower than revenue, as the company has not yet established a consistent track record of financial performance. Since the company does not pay dividends, the Dividend Yield and Payout Ratio are both N/A or 0.0%, indicating that the organization reinvests all available resources, including its $11.49M cash reserve, back into its proprietary hydrogel technology and development pipeline. The overall growth and income profile is characterized by a total absence of current income generation and measurable growth rates, relying entirely on the potential future success of its medical device hydrogels to transform its financial status from a cash-burning entity to a profitable one.